SEARCH

SEARCH BY CITATION

References

  • 1
    McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 13581364.
  • 2
    McGory R. Pharmacoeconomic analysis of HBV liver transplant therapies. Clin Transplant 2000; 14(Suppl 2): 2938.
  • 3
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 16151621.
  • 4
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585589.
  • 5
    Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med 2003; 253: 544552.
  • 6
    Fagiuali S, Mirante VG, Pompili M, Gianni S, Leandro G, Rapaccini GL, et al. Liver transplantation: the Italian experience. [Comment]. Dig Liver Dis 2002; 34: 640648.
  • 7
    Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 11791186.
  • 8
    Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003; 75: S41S44.
  • 9
    Zheng S, Wu J, Wang W, Huang D, Liang T, Lu A. Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation. Chung-Huai Hsueh Tsa Chih [Chinese Medical Journal] 2002; 82: 445448.
  • 10
    Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl 2002; 8: 29.
  • 11
    van Nunen AB, de Man RA, Heijtink RA, Vossen AC, Schalm SW. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepat 2002; 9: 221228.
  • 12
    Villamil FG. Hepatitis B: progress in the last 15 years. Liver Transpl 2002; 8: S59S66.
  • 13
    Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 12121215. [Erratum appears in Lancet 1997;349(9048):364].
  • 14
    Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434439.
  • 15
    Kruger M. European hepatitis B immunoglobulin trials: prevention of recurrent hepatitis B after liver transplantation. Clin Transplant 2000; 14(Suppl 2): 1419.
  • 16
    Perrillo RP. Antiviral therapy to prevent and treat hepatitis B virus infection in hepatic allografts. Clin Transplant 2000; 14(Suppl 2): 2528.
  • 17
    Perrillo RP, Kruger M, Sievers T, Lake JR. Posttransplantation: emerging and future therapies. Semin Liver Dis 2000; 20(Suppl 1): 1317.
  • 18
    Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmacher U, et al. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 2002; 40: 795799.
  • 19
    Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002; 8: S67S73.
  • 20
    Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: insights into management. Liver Transpl Surg 1995; 1: 8999.
  • 21
    Nery JR, Weppler D, Lavandera R, Nery Avila C, Magill A, Rodriguez M, et al. Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Transplant Proc 1999; 31: 485486.
  • 22
    Samuel D, Bismuth H. Liver transplantation for hepatitis B. Gastroenterol Clin North Am 1993; 22: 271283.
  • 23
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424432.
  • 24
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741748.
  • 25
    Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 15281535.
  • 26
    Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 8695.
  • 27
    Ben-Ari Z, Mor E, Manhaim V, Barak O, Bar-Nathan N, Shaharabani E, et al. Passive immunization with OMRI-Hep-B for prevention of hepatitis B virus reinfection after liver transplantation. Transplant Proc 2001; 33: 28952896.
  • 28
    Buti M, Esteban R. Adefovir dipivoxil. Drugs Today (Barc) 2003; 39: 127135.